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Abstract
Infection by d-retroviruses such as human T-lymphotropic virus type 1 (HTLV-1) and bovine leukemia virus (BLV) is mostly
asymptomatic. Indeed, only a minority (,5%) of d-retrovirus infected hosts will develop either lymphoproliferative or
neurodegenerative diseases after long latency periods. In fact, the host immune response is believed to tightly control viral
replication but this assumption has not been definitely proven in vivo. Here, we provide direct experimental evidence
demonstrating that integrity of the spleen is required to control pathogenesis. In the BLV model, we show that asplenia
decreases efficiency of the immune response and induces an imbalance in cell dynamics resulting in accelerated onset of
leukemia. These observations enlighten a potential threat in splenectomized HTLV-1 carriers and justify a regular preventive
evaluation.
Citation: Florins A, Reichert M, Asquith B, Bouzar A-B, Jean G, et al. (2009) Earlier Onset of d-Retrovirus-Induced Leukemia after Splenectomy. PLoS ONE 4(9):
e6943. doi:10.1371/journal.pone.0006943
Editor: Reuben S. Harris, University of Minnesota, United States of America
Received July 8, 2009; Accepted August 4, 2009; Published September 14, 2009
Copyright:  2009 Florins et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: We thank the Sixth Research Framework Programme of the European Union (project INCA LSHC-CT-2005-018704), the ‘‘Belgian Foundation against
Cancer’’, the Bekales Foundation and the ‘‘Fonds national de la recherche scientifique’’ (FNRS), the ‘‘Neoangio’’ excellence program of the ‘‘Direction generale des
Technologies, de la Recherche et de l’energie’’ of the Walloon government and the ‘‘Action de Recherche Concertee, ‘‘Glyvir’’ of the ‘‘Communaute Francaise de
de Belgique’’ for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: florins.a@fsagx.ac.be
Introduction
Surgical removal of the spleen is performed for a number of
reasons, including trauma and different pathologic conditions such
as hematological disorders, hypersplenism or splenomegaly.
Although the risk of overwhelming postsplenectomy infections by
encapsulated bacteria has been clearly documented [1,2], the
question whether asplenia plays a role in cancer development have
yielded conflicting results [3–9]. On one hand, no increase in
cancer risk was detected among patients having experienced a
splenectomy for trauma [9]. On the other hand, clinical evidence
indicates that splenectomy increases the risk of secondary breast
cancer and acute nonlymphocytic leukemia in patients treated for
Hodgkin’s disease [10–12]. Accelerated leukemia/lymphoma
progression has also been reported after splenectomy in NK cell
leukemia and in large granular lymphocyte leukemia [13,14].
Among 20 million HTLV-1 infected subjects worldwide, a
proportion will undergo splenectomy for traumatic or diagnostic
purposes. Since complications of asplenia in HTLV-1 carriers are
presently unknown and cannot be experimentally tested, we evaluated
the risk associated with splenectomy in an animal model: bovine
leukemia virus (BLV)-infected sheep. HTLV-1 and BLV are two
related d-retroviruses infecting CD4+ in humans and B lymphocytes
in ruminants, respectively [15]. Both viruses share common epitopes
in the gag-encoded capsid antigens further supporting a close
evolutionary relationship between the two viruses. Genomic organi-
zation and gene functions are also remarkably similar: in addition to
the structural gag, pol and env genes required for the synthesis of the
viral particle, both viral genomes contain a particular region
pertaining to the d-retrovirus genus and coding for regulatory
proteins. Common features of HTLV-1 and BLV pathogeneses
include horizontal transmission, cell-associated infection, random
integration into the host genome, dual routes of viral replication (i.e.
mitotic and infectious) and accelerated cell turnover.
In view of the similarities between the two viruses in terms of
pathogenic mechanisms, we think that improved understanding in
the BLV model may be informative for HTLV-1. In this context,
we addressed the role of asplenia in BLV-infected sheep.
Methods
Ethics statement
Handling of sheep and experimental procedures were approved
by the ethic committee (local ethic committee of Gembloux
Agricultural University; C.L.E.) and were conducted in accordance
with institutional and national guidelines for animal care and use.
Experimental animals, splenectomy and sample collection
50 sheep were maintained under restricted conditions (L2) either at
the Veterinary and Agrochemical Research Center (Machelen,
Belgium), the Study Center of Animal Productions (Gembloux,
Belgium) or the National Veterinary Research Institute (Pulawy,
Poland). 40 sheep were experimentally infected with the wild type
BLV strain 344 [16]. Ten BLV-infected sheep and 3 controls were
splenectomized at 4.663.2 months post-infection. For splenectomy,
sheep were anesthetized by intravenous injection of approximately
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perfusion of 2 ml/hour during the surgery. The spleen was then
removed after ligature of the splenic vein and artery of sheep. At
regular intervals of time, blood samples were collected by jugular
venipuncture, mixed with anticoagulant (either with 0.3% w/v of
EDTA or 10 U/ml of heparin). Leukocyte and lymphocyte counts
were determined using an automated cell counter (MS 4-5 vet Mellet
Schloesing Laboratories). Peripheral blood mononuclear cells
(PBMCs) were isolated by Percoll density gradient centrifugation
(GE Healthcare) and washed twice with PBS/0.075% EDTA and at
least three times with PBS alone to eliminate platelets. PBMCs were
either cryopreserved in DMSO/fetal calf serum (10/90 v/v) or
directly used for analysis.
In vivo cell kinetics measurement
In vivo cell turnover parameters were estimated by intravenous
injection of 5-bromo-29-deoxyuridine (BrdU) and carboxyfluor-
escein diacetate succinimidyl ester (CFSE). BrdU incorporates into
the DNA of cells undergoing proliferation mainly in lymphoid
tissues whereas CFSE labels $98% of resting and proliferating
peripheral blood mononuclear cells [17,18]. PBMCs were
prepared at regular intervals of time and labeled with a
monoclonal antibody directed against immunoglobulin M (anti-
IgMs, mouse IgG1) and with a rat anti-mouse IgG1 phycoerythrin
(PE)-antibody (Becton Dickinson Immunocytometry Systems). For
BrdU labeling, cells were fixed with PBS/4% paraformaldehyde,
treated with FACS permeabilizing solution (Becton Dickinson
Immunocytometry Systems), and stained with anti-BrdU FITC
antibody in the presence of DNAse (Becton Dickinson Immuno-
cytometry Systems). The percentages of BrdU+ and CFSE+ B cells
were then determined by flow cytometry (FACS Aria, Becton
Dickinson Immunocytometry Systems).
Proliferation and death rates were estimated by fitting
mathematical models to BrdU and CFSE labeling data obtained
by flow cytometry [17–19]. These models basically use two sets of
data from the flow cytometry analyses: the proportion of labeled
Figure 1. Evaluation of proliferation rates in vivo. BrdU was injected intravenously in BLV infected sheep and in non infected controls. At
regular interval of time, the percentage of B lymphocytes having incorporated BrdU was determined by flow cytometry. A mathematical model was
fitted to in vivo BrdU labeling data in B lymphocytes and proliferation rates were estimated. Not splenectomized (left panels) and splenectomized
(right panels) animals were analyzed. (A) Percentage of B cells having incorporated BrdU in BLV-infected (&) and control (m) sheep. (B) Mean values
(6SD) of proliferation rates. BrdU was injected in 13 infected sheep, 4 of them being splenectomized and 6 controls, 3 of them being splenectomized.
Statistical relevance (n.s., not significant; p,0.01, highly statistically significant**) was calculated according to the unpaired two-tailed student t test
with Welch’s correction.
doi:10.1371/journal.pone.0006943.g001
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two types of experimental data allows calculation of the
proliferation and death rates, the latter parameter also including
the disappearance of the cells out of the blood.
Evaluation of immune response ex vivo
The principle of the technique is based on the antigenic
stimulation of blood samples with BLV proteins expressed by fetal
lamb kidney cells (FLK-BLV). Confluent FLK-BLV cultures (250
cells/ml) were lysed by 3 freeze-thaw cycles, dislocated by
sonication, centrifuged for 10 minutes at 3000 g and stored in
aliquots at 270uC. Heparinized blood was regularly collected and
mixed with an equal volume of RPMI 1640 medium supplement-
ed with 10% FCS, 2 mM L-glutamine, 100 U/ml of penicillin,
100 U/ml of streptomycin and 1 mM of sodium pyruvate. Blood
and FLK-BLV precleared lysates were then mixed in a 4/1
proportion (v/v) and incubated in a 5% CO2-air atmosphere at
37uC during 5 days. After culture, brefeldin A (5 mg/ml) was
added during 4 hours and red blood cells were lysed with 1X
FACS Lysing Solution (Becton Dickinson Immunocytometry
Systems) for 15 min at room temperature. Leukocytes were
permeabilized in PBS-0.1% saponin, stained with monoclonal
antibodies directed against CD8 (CACT80C, mouse IgG1) and
perforin (DeltaG9, mouse IgG2A) and then labeled with rat anti-
mouse IgG1-FITC and rat anti-mouse IgG2a+b-PE conjugates.
Finally, the percentages of CD8+ perforin + cells were determined
by flow cytometry.
Determination of proviral loads and viral expression in
vivo
Proviral loads were evaluated by real time PCR as previously
described [20]. Quantification of BLV RNA expression was
determined as follows: 500 ng of RNA were first reverse transcribed
into cDNA using Euroscript reverse transcriptase (Eurogentec) and
Figure 2. Evaluation of death rates in vivo. CFSE was injected intravenously in BLV infected sheep and in non infected controls. At regular
interval of time, the percentage of B lymphocytes labeled with CFSE was determined by flow cytometry. A mathematical model was fitted to in vivo
CFSE labeling data in B lymphocytes and death rates were estimated. Not splenectomized (left panels) and splenectomized (right panels) animals
were analyzed. (A) Percentages of B cells labeled with CFSE in BLV-infected (&) and control (m) sheep. (B) Mean values (6SD) of death rates. CFSE
was injected in 7)infected sheep, 3 of them being splenectomized and 7 controls, 3 of them being splenectomized. Statistical relevance (n.s., not
significant; p,0.05, statistically significant*; p,0.01, highly statistically significant**) was calculated according to the unpaired two-tailed student t
test with Welch’s correction.
doi:10.1371/journal.pone.0006943.g002
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by AmpliTaq Gold DNA polymerase (Applied Biosystems) on a
Stepone apparatus (Applied Biosystems) using a pair of primers
(400 nM of 59-CAGCACAATGAAGATCAAGATCATC-39/59-
CGGACTCATCGTACTCCTGCTT-39 or 400 nM of 59-GC-
CTTCAAATGCCTAAAGAACG-39/59-CGGGCAGGCATGT-
AGAGAGT-39, respectively) and revealed with Black Hole Quencher
splice junction probes (100 nM of 59FAM-TCGCTGTCCAC-
CTTCCAGCAGATGT-39BHQ1 or 60 nM of 59FAM-CAACAA-
CACTTGCCATCTGATGATCG-39BHQ1, respectively).
To determine the RNA copy numbers, b-actinand Tax amplicons
were first cloned into plasmid pCR4-TOPO (Invitrogen) and
transcribed in vitro (Megascript; Ambion). 10
2 to 10
6 RNA copies of
each transcript were then reverse transcribed and amplified as
described above. These standard curves allowed absolute quantifica-
tion of Tax and b-actin copy numbers in samples.
Results
Cell proliferation and death can be quantified in BLV-infected
sheep using CFSE and BrdU kinetic profiles. CFSE preferentially
labels peripheral blood cells whereas BrdU is incorporated upon
proliferation mainly in lymphoid tissues [17,18,20]. To evaluate
the role of the spleen in B cell dynamics, BrdU and CFSE were
injected intravenously before or after splenectomy in BLV–
infected and control sheep. The proportion of cells labeled with
BrdU (figure 1A) and CFSE (figure 2A) were then measured by
flow cytometry at different times in non-operated (left panels) and
asplenic sheep (right panels). The proportion of B cells having
incorporated BrdU reached a maximum (3.5% at day 3 in a
representative infected sheep & and 1.4% at day 2 m in a control;
figure 1A, left panel) and then progressively decreased. Mathe-
matical modeling of BrdU experimental data in a series of sheep
showed that B cell proliferation was increased in BLV-infected
animals (figure 1B, left panel; p,0.01). Upon splenectomy, this
difference in B cell proliferation between BLV-infected and
control sheep was conserved (figure 1B, right panel; p,0.01).
Next, the disappearance rate of peripheral blood B cells was
quantified by CFSE kinetic profiles (figure 2A). Intravenous CFSE
injection labeled more than 98% of peripheral blood B cells
independently of BLV infection and splenectomy (data not shown).
Modeling these CFSE data showed that, in eusplenic sheep, B cells
died significantly more rapidly in BLV-infected than in control sheep
(figure 2B, left panel; p,0.01) and that this difference in death rates
Figure 3. Influence of splenectomy on B cells counts, proviral loads and in vivo viral expression. 20 sheep were infected with BLV. A few
months after seroconversion (average delay: 4.6 months), 10 of them were splenectomized. Blood was collected at regular intervals of time and
different parameters were measured. Each value represents the average of 3 representative data in not splenectomized (&) and splenectomized (m)
animals. (A) Numbers of B lymphocytes/mm
3 of blood. (B) Proviral loads (in numbers of viral copies/mm
3 of blood were determined by real time PCR
and normalized to the blood volume. (C) Proportions between tax and actin transcripts (in arbitrary units) were measured by real time RT-PCR and
normalized to the blood volume.
doi:10.1371/journal.pone.0006943.g003
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a lysate from FLK-BLV cells. After 5 days of culture, brefeldin A was added during 4 hours, leukocytes were permeabilized and CD8 and perforin
expression were quantified by flow cytometry. (A) Representative dot plots of CD8 (x axis) and perforin (y axis) labeling of leukocytes from control,
infected and splenectomized infected sheep, with and without antigenic stimulation. (B) Induction of perforin expression calculated as the ratio
between the proportion of CD8 expressing perforin with and without antigenic stimulation. These values were measured 4 times (during a 3 months
period) in control, BLV-infected and splenectomized BLV-infected sheep. Statistical relevance (N.S. not significant; *** very highly statistically
significant p,0.001) was calculated according to the unpaired two-tailed student t test with Welch’s correction.
doi:10.1371/journal.pone.0006943.g004
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BLV-infected sheep, splenectomy induced a significant decrease in cell
death rates (Figure 2B, compare left and right panels, p,0.05).
Fitting all kinetic parameters together (compare panels 1B and
2B) thus reveals an imbalance of the cell turnover in BLV-infected
asplenic sheep. To correlate this modification in cell dynamics with
viral replication, the proviral loads were compared in 20 BLV-
infected sheep, 10 of them having been splenectomized. Consis-
tently, splenectomy increased the numbers of B lymphocytes in the
peripheral blood (Figure 3A; compare & and m;p ,0.01). Asplenic
animals also had significantly higher DNA proviral loads and
increased viral expression (Figure 3B and 3C; p,0.01).
The present knowledge of BLV replication postulates that the
proviral load is tightly controlled by the host immune response and
more particularly by cytotoxic T cells [21]. In this context, the
increased proviral loads observed in splenectomized sheep may be
due to a reduction of immune surveillance. Therefore, the ability
of BLV antigens to stimulate CD8+ lymphocytes was compared in
splenectomized and eusplenic sheep. The principle of the
technique is based on stimulation of perforin expression by
CD8+ T cells in presence of BLV proteins from a lysate of FLK-
BLV cells. To closely mimic CTL response undergoing in vivo, the
assay is performed in cultures of heparinized blood simply diluted
twofold in RPMI medium. Representative flow cytometry analyses
(figure 4A) show that the percentages of CD8+ cells expressing
perforin upon antigen stimulation increase in BLV-infected sheep
cultures (middle panels) but not in the control (left panels).
Importantly, splenectomy abrogates perforin stimulation in CD8
lymphocytes from BLV-infected splenectomized sheep (Figure 4A,
right panels). The same experiment repeated 4 times over a 3
months period in 9 sheep confirmed the lack of CD8+ activation
after splenectomy (Figure 4B).
Together, these data strongly support a major role exerted by
the spleen to control viral replication via a CD8+ mediated cell
response. In contrast, no significant difference was observed in the
virus-specific antibody titers (i.e. antibodies directed against the
gp51 viral envelope protein, data not shown), further supporting a
predominant effect of the cytotoxic response compared to the
humoral immune surveillance.
Failure of an efficient immune control of viral replication is
consistent with an increase in proviral loads (Figure 3B) and a
reduction in cell death rates in vivo (Figure 2B). It is also expected
that favored viral replication induces a faster accumulation of
infected B cells in asplenic animals (Figure 3A). Interestingly,
amongst 10 splenectomized BLV-infected sheep, 9 developed
acute leukemia (leukocyte counts .40,000/mm
3) after unusually
short latency periods (Figure 5). The mean delay between infection
and onset of leukemia was only 1.2360.60 years in asplenic sheep
compared to 2.3261.15 years in 29 non-splenectomized controls
(p,0.001). These observations clearly assess a major role of the
spleen in disease progression in BLV-infected sheep.
Discussion
The most straightforward contribution of this paper is that
splenectomy accelerates leukemogenesis induced by BLV in sheep.
Assessment of in vivo cell kinetics (Figures 1 and 2) reveals a
disequilibrium in cell death rates leading, in the absence of
compensatory change in proliferation rates, to the progressive
accumulation of infected cells in asplenic animals (Figure 3).
Earlier onset of leukemia in splenectomized sheep also correlates
with an impairment of a BLV-specific immune response (Figure 4).
Our results therefore indicate that disease acuteness is linked to an
impairment of cytotoxic response against BLV.
Although consistent with the data, this simplified model should
be put into perspective. First, we cannot formally exclude that the
humoral response does not control expansion of infected cells
although antibodies directed against the gp51 viral envelope
protein remain constant upon splenectomy. It remains indeed
possible that the titers of other antiviral antibodies are modified in
asplenic sheep. Second, the increased number of B lymphocytes
observed after splenectomy is not specific to BLV infection. In fact,
this surgery also increases the cell counts in non-infected sheep
(data not shown) as observed in other species [22,23]. Third,
splenectomy does not appear to modify the capacity of the virus to
be expressed ex vivo and in vivo. In fact, the relative proportions of
BLV-expressing cells measured in short term cultures as well as the
tax/b-actin mRNA ratio determined by real time RT-PCR are
not significantly affected by splenectomy (data not shown). This
observation indicates that the spleen integrity does not modulate
viral expression in infected cells and suggests that the virus
continuously attempts to replicate independently of the immune
response. Fourth, susceptibility of infected B cells to undergo
spontaneous apoptosis ex vivo is not modified by splenectomy (data
not shown). Since CFSE kinetic profiles clearly demonstrate that
the disappearance rates of infected B lymphocytes is reduced upon
splenectomy (Figure 2), this data indicates that these cells have a
similar intrinsic capacity to survive upon short term culture but are
destroyed by the immune response in vivo. This elimination of
infected cells occurs at lower rates in the absence of spleen. In
consequence, splenectomized BLV-infected sheep accumulate B
cells with extended lifetime. This process may favor accumulation
of genetic defects leading to a higher probability of transformation
and reducing latency period before onset of leukemia.
We have demonstrated here that the spleen is a major
component of the host immune control of viral pathogenesis. Cell
kinetics measurements show that B cells in splenectomized sheep
have a defect in cell death compared to controls (Figure 2). It is
likely that this disequilibrium accelerates onset of leukemia in
splenectomized animals. However, CFSE labeling data show that
Figure 5. Development of leukemia in splenectomized animals.
10 BLV-infected sheep were splenectomized a few months after
seroconversion (average delay: 4.6 months). Mean (6SD) latency
periods (time between seroconversion and leukaemia; leukocytes
counts .40 000/mm
3) in non operated BLV-infected sheep (n=29)
and in splenectomized sheep (n=9). Statistical relevance (p,0.001, very
highly statistically significant ***) was calculated according to the
unpaired two-tailed student t test with Welch’s correction.
doi:10.1371/journal.pone.0006943.g005
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per day, providing that all other parameters remain constant.
Since very fast onset of leukemia was definitely not observed
immediately after surgery (i.e. within days), other regulatory
mechanisms are predicted to maintain homeostasis such as
enhanced recirculation to other lymphoid organs, decreased cell
production/differentiation or accumulation in other tissues.
The mechanism outlined in this report may also be informative
for the pathogenesis induced by the related HTLV-1 in particular
for ATL. Although splenectomy has recently been proposed as an
optional treatment for hypersplenism caused by ATL [24], the
consensus policy includes chemotherapy, antiviral therapy and
allogeneic hematopoietic stem-cell transplantation [25]. In specific
cases, splenectomy may therefore be considered as a palliative
treatment for pain relief. The observations of this report enlighten
another important aspect of asplenism in HTLV carriers. When
splenectomy has to be performed due to traumatic or possibly
diagnostic purposes, there is a potential risk for accelerating onset
of ATL in these subjects. Therefore, HTLV-1 infected asymp-
tomatic carriers undergoing splenectomy would require a more
regular preventive evaluation of their clinical stage.
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